Convert Pharmaceuticals is a clinical-stage biotech company, developing a proprietary pipeline of biomarker-enabled hypoxia-activated prodrugs to treat resistant solid tumors
Convert Pharmaceuticals is a clinical-stage biotech company, developing a proprietary pipeline of biomarker-enabled hypoxia-activated prodrugs to treat resistant solid tumors.